CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced that its Board of Directors has authorized the expansion of its common stock repurchase program by an additional $40 million following the receipt of a $40 million payment from Eli Lilly and Co. (Lilly). Alkermes also raised its fiscal year 2009 financial guidance.
